Tuesday, November 16, 2010
Dendreon is developing an HER-2 Theraputic vaccine called Neuvenge. This is an antigen expressed by breast, bladder, gastric, colorectal and ovarian cancer.
This is another new paradigm drug that could save more millions of lives.
If this is given before any other procedures it may be the only needed therapy.
This would really shakeup the oncology industry. $60 billion/yr reduced. WOW!
Labels:
Bladder cancer,
Breast cancer,
Colorectal cancer,
HER-2,
Neuvenge,
Ovarian cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment